Physician profile
Ghassan Kamel
NPI 1700174638
$28,152.43
in general payments reported to CMS, 2019-2025
11 companies · $6,061 in 2025
The $6,061 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2021: $1,922 · 2022: $7,966 · 2023: $9,851 · 2024: $2,185 · 2025: $6,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Food and Beverage: $1,912 · Travel and Lodging: $962 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,023.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Food and Beverage | $1,911.76 |
| Travel and Lodging | $962.07 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $11,981.68 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $7,837.63 | 2022-2025 | Tezspire, Fasenra |
| Genentech USA, INC. | $7,538.03 | 2019-2025 | |
| Inari Medical, INC. | $343.06 | 2022 | |
| Glaxosmithkline, LLC. | $136.86 | 2019-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Abiomed | $99.70 | 2025 | |
| Abbott Laboratories | $64.97 | 2024 | 2nd Gen Centrimag Primary Console |
| Regeneron Pharmaceuticals, INC. | $20.85 | 2023 | Dupixent |
| Boston Scientific Corporation | $17.00 | 2021 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghassan Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.